Roche Gains FDA Approval for New Subcutaneous Formulation of ACTEMRA for Use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
Oct 23, 2013
Roche Gains FDA Approval for New Subcutaneous Formulation of ACTEMRA for Use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
Roche Gains FDA Approval for New Subcutaneous Formulation of ACTEMRA for Use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis
